Medicine and Dentistry
Optical Coherence Tomography Angiography
100%
Wet Macular Degeneration
82%
Retina Vein Occlusion
79%
Optical Coherence Tomography
78%
Insulin Dependent Diabetes Mellitus
72%
Visual Acuity
69%
Epidemiology of Diabetes
66%
Diabetes Control and Complications Trial
66%
Diseases
64%
Vasculotropin
59%
Age Related Macular Degeneration
56%
Aflibercept
51%
Retinopathy
51%
Cardiovascular Disease
51%
Diabetic Retinopathy
47%
Maculopathy
47%
Choroidal Neovascularization
45%
Autofluorescence
41%
Retinal Detachment
41%
Macular Degeneration
38%
Multimodal Imaging
36%
Eye Disease
32%
Retina Blood Vessel Occlusion
31%
Contrast Sensitivity Testing
31%
Contrast Sensitivity
27%
Ranibizumab
23%
Bevacizumab
23%
Capillary
23%
Retinal Imaging
23%
Cardiovascular System
22%
Prevalence
22%
Dystrophy
22%
Ophthalmology
21%
Angiography
21%
Agents Acting on the Eye
20%
Screening
19%
Spectral Domain Optical Coherence Tomography
19%
Glycemic Control
19%
Diabetes Mellitus
19%
Diabetes
18%
Vascularity
18%
Patient Referral
18%
Hydroxychloroquine
17%
Awareness
17%
Primary Health Care
17%
Cardiovascular Risk
17%
Best Corrected Visual Acuity
17%
Diagnosis
15%
Alanine Aminotransferase
15%
Telemedicine
15%
Keyphrases
Retinal Vein Occlusion
79%
Neovascular Age-related Macular Degeneration (nAMD)
79%
Diabetes Complications
78%
Diabetes Control
67%
Diabetes Intervention
67%
Diabetes Epidemiology
67%
Type 1 Diabetes Mellitus (T1DM)
64%
Age-related Macular Degeneration
63%
Optical Coherence Tomography Angiography (OCT-A)
57%
Aflibercept
53%
Visual Acuity
50%
Swept-source Optical Coherence Tomography (SS-OCT)
47%
Intravitreal Aflibercept
47%
Myopic Choroidal Neovascularization (mCNV)
45%
Pigment Epithelial Detachment
42%
Fundus Autofluorescence
41%
Type I Diabetes
40%
Retinopathy
40%
Diabetic Retinopathy
39%
Multimodal Imaging
36%
Cardiovascular Disease
35%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
35%
Optical Coherence Tomography
35%
Anti-vascular Endothelial Growth Factor Therapy
33%
Contrast Sensitivity
31%
Sensitivity Test
31%
Diamond
31%
Bevacizumab
26%
Ranibizumab
26%
Macular
26%
Retina
26%
Subretinal Fluid
26%
Visual Outcome
25%
Retinal Imaging
24%
Treat-and-extend
23%
Older Men
23%
Intravitreal Ranibizumab
22%
Non-mydriatic
22%
Choriocapillaris
22%
Visual Acuity Outcome
21%
Glycemic Control
21%
Baseline Visual Acuity
20%
Cardiovascular Risk
19%
Myopia
19%
Dosing Regimen
19%
Diabetic Macular Edema
19%
Best-corrected Visual Acuity
19%
Anatomical Outcome
19%
Nonperfusion
18%
Hyperreflectivity
18%